JP2000511411A - 抗―肺炎球菌ワクチン用のコリン結合タンパク質 - Google Patents

抗―肺炎球菌ワクチン用のコリン結合タンパク質

Info

Publication number: JP2000511411A
Authority: JP; Japan
Prior art keywords: binding protein; choline binding; streptococcal; choline; cbp
Prior art date: 1996-05-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP09539170A

Other languages

English (en)

Japanese (ja)

Other versions

JP2000511411A5 (2

Inventor

エイチロバートマーズア

カーステンアイローズナウ

エレイントゥーマネン

テレーザエムウィーゼマン

Original Assignee

ザロックフェラーユニヴァーシティ

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-01

Filing date

1997-05-01

Publication date

2000-09-05

1997-05-01 Application filed by ザロックフェラーユニヴァーシティ filed Critical ザロックフェラーユニヴァーシティ

2000-09-05 Publication of JP2000511411A publication Critical patent/JP2000511411A/ja

2005-01-13 Publication of JP2000511411A5 publication Critical patent/JP2000511411A5/ja

Status Pending legal-status Critical Current

Links

101710164918 Choline-binding protein Proteins 0.000 title claims abstract description 285
230000003497 anti-pneumococcal effect Effects 0.000 title description 6
229940124733 pneumococcal vaccine Drugs 0.000 title description 3
108090000623 proteins and genes Proteins 0.000 claims abstract description 178
102000004169 proteins and genes Human genes 0.000 claims abstract description 128
241000894006 Bacteria Species 0.000 claims abstract description 97
229960001231 choline Drugs 0.000 claims abstract description 80
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims abstract description 79
238000000034 method Methods 0.000 claims abstract description 72
239000012634 fragment Substances 0.000 claims abstract description 59
230000001580 bacterial effect Effects 0.000 claims abstract description 56
108010067306 Fibronectins Proteins 0.000 claims abstract description 54
229960005486 vaccine Drugs 0.000 claims abstract description 46
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 43
108010022181 Phosphopyruvate Hydratase Proteins 0.000 claims abstract description 33
102000012288 Phosphopyruvate Hydratase Human genes 0.000 claims abstract description 32
239000003112 inhibitor Substances 0.000 claims abstract description 23
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
230000027455 binding Effects 0.000 claims description 99
238000009739 binding Methods 0.000 claims description 93
108020004414 DNA Proteins 0.000 claims description 51
108091016312 choline binding proteins Proteins 0.000 claims description 33
108090000765 processed proteins & peptides Proteins 0.000 claims description 33
108091007433 antigens Proteins 0.000 claims description 30
102000036639 antigens Human genes 0.000 claims description 30
239000000427 antigen Substances 0.000 claims description 29
208000015181 infectious disease Diseases 0.000 claims description 27
125000003275 alpha amino acid group Chemical group 0.000 claims description 26
102000053602 DNA Human genes 0.000 claims description 24
102000004190 Enzymes Human genes 0.000 claims description 24
108090000790 Enzymes Proteins 0.000 claims description 24
230000000694 effects Effects 0.000 claims description 23
239000002671 adjuvant Substances 0.000 claims description 22
239000002773 nucleotide Substances 0.000 claims description 20
125000003729 nucleotide group Chemical group 0.000 claims description 20
208000035143 Bacterial infection Diseases 0.000 claims description 19
208000022362 bacterial infectious disease Diseases 0.000 claims description 19
241000283973 Oryctolagus cuniculus Species 0.000 claims description 18
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 18
102000004196 processed proteins & peptides Human genes 0.000 claims description 18
102000039446 nucleic acids Human genes 0.000 claims description 17
108020004707 nucleic acids Proteins 0.000 claims description 17
241000894007 species Species 0.000 claims description 17
108091026890 Coding region Proteins 0.000 claims description 16
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 16
210000004072 lung Anatomy 0.000 claims description 16
150000007523 nucleic acids Chemical class 0.000 claims description 16
108020004705 Codon Proteins 0.000 claims description 15
108020004511 Recombinant DNA Proteins 0.000 claims description 15
238000009396 hybridization Methods 0.000 claims description 15
229920001184 polypeptide Polymers 0.000 claims description 15
239000004480 active ingredient Substances 0.000 claims description 14
108091034117 Oligonucleotide Proteins 0.000 claims description 13
-1 cation small molecule Chemical class 0.000 claims description 13
239000004472 Lysine Substances 0.000 claims description 12
239000008280 blood Substances 0.000 claims description 12
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 11
241000194017 Streptococcus Species 0.000 claims description 10
239000003242 anti bacterial agent Substances 0.000 claims description 9
230000002358 autolytic effect Effects 0.000 claims description 9
210000004369 blood Anatomy 0.000 claims description 9
229940088710 antibiotic agent Drugs 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
238000010828 elution Methods 0.000 claims description 8
230000002285 radioactive effect Effects 0.000 claims description 8
239000004475 Arginine Substances 0.000 claims description 7
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
230000009089 cytolysis Effects 0.000 claims description 7
201000010099 disease Diseases 0.000 claims description 7
125000000539 amino acid group Chemical group 0.000 claims description 6
108091008324 binding proteins Proteins 0.000 claims description 6
239000003795 chemical substances by application Substances 0.000 claims description 6
238000004587 chromatography analysis Methods 0.000 claims description 6
238000001514 detection method Methods 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 6
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 5
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 5
150000002540 isothiocyanates Chemical class 0.000 claims description 5
150000003431 steroids Chemical class 0.000 claims description 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 3
150000001768 cations Chemical class 0.000 claims description 3
230000002401 inhibitory effect Effects 0.000 claims description 3
230000036961 partial effect Effects 0.000 claims description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 2
102100037362 Fibronectin Human genes 0.000 claims 3
206010070834 Sensitisation Diseases 0.000 claims 3
230000008313 sensitization Effects 0.000 claims 3
230000000935 anti-streptococcal effect Effects 0.000 claims 2
102000023732 binding proteins Human genes 0.000 claims 2
229940124840 Streptococcal vaccine Drugs 0.000 claims 1
102000021127 protein binding proteins Human genes 0.000 claims 1
108091011138 protein binding proteins Proteins 0.000 claims 1
229940023143 protein vaccine Drugs 0.000 claims 1
102000016359 Fibronectins Human genes 0.000 abstract description 51
230000003053 immunization Effects 0.000 abstract description 15
238000002649 immunization Methods 0.000 abstract description 14
241000192125 Firmicutes Species 0.000 abstract description 13
150000003384 small molecules Chemical class 0.000 abstract description 9
230000001404 mediated effect Effects 0.000 abstract description 6
235000018102 proteins Nutrition 0.000 description 121
210000004027 cell Anatomy 0.000 description 94
239000000203 mixture Substances 0.000 description 84
238000009472 formulation Methods 0.000 description 43
235000001014 amino acid Nutrition 0.000 description 34
229940024606 amino acid Drugs 0.000 description 34
150000001413 amino acids Chemical class 0.000 description 33
108010040473 pneumococcal surface protein A Proteins 0.000 description 32
241000193998 Streptococcus pneumoniae Species 0.000 description 30
229940031000 streptococcus pneumoniae Drugs 0.000 description 30
239000013598 vector Substances 0.000 description 28
241001465754 Metazoa Species 0.000 description 25
210000002966 serum Anatomy 0.000 description 21
230000002950 deficient Effects 0.000 description 20
238000003556 assay Methods 0.000 description 19
239000000843 powder Substances 0.000 description 18
241000699670 Mus sp. Species 0.000 description 17
229940088598 enzyme Drugs 0.000 description 17
239000003446 ligand Substances 0.000 description 17
238000002360 preparation method Methods 0.000 description 17
238000011282 treatment Methods 0.000 description 17
101100166331 Dictyostelium discoideum cbpP gene Proteins 0.000 description 16
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
101100167697 Synechococcus elongatus (strain PCC 7942 / FACHB-805) cmpA gene Proteins 0.000 description 16
101150033736 cbpA gene Proteins 0.000 description 16
230000006870 function Effects 0.000 description 16
210000005265 lung cell Anatomy 0.000 description 16
239000002953 phosphate buffered saline Substances 0.000 description 16
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
210000002889 endothelial cell Anatomy 0.000 description 15
230000001225 therapeutic effect Effects 0.000 description 15
230000000890 antigenic effect Effects 0.000 description 14
229940079593 drug Drugs 0.000 description 14
239000003814 drug Substances 0.000 description 14
238000005516 engineering process Methods 0.000 description 14
238000002474 experimental method Methods 0.000 description 13
238000004519 manufacturing process Methods 0.000 description 13
239000000047 product Substances 0.000 description 13
239000000243 solution Substances 0.000 description 13
239000000126 substance Substances 0.000 description 13
239000000443 aerosol Substances 0.000 description 12
239000005557 antagonist Substances 0.000 description 12
239000011324 bead Substances 0.000 description 12
229960002897 heparin Drugs 0.000 description 12
229920000669 heparin Polymers 0.000 description 12
210000005260 human cell Anatomy 0.000 description 12
239000002609 medium Substances 0.000 description 12
238000003752 polymerase chain reaction Methods 0.000 description 12
238000000746 purification Methods 0.000 description 12
239000000523 sample Substances 0.000 description 12
229940125575 vaccine candidate Drugs 0.000 description 12
230000001018 virulence Effects 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical group OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 11
108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 11
102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 11
239000002253 acid Substances 0.000 description 11
239000003153 chemical reaction reagent Substances 0.000 description 11
239000013612 plasmid Substances 0.000 description 11
238000001262 western blot Methods 0.000 description 11
238000003745 diagnosis Methods 0.000 description 10
210000003527 eukaryotic cell Anatomy 0.000 description 10
108010037896 heparin-binding hemagglutinin Proteins 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 10
239000000463 material Substances 0.000 description 10
238000012216 screening Methods 0.000 description 10
238000012360 testing method Methods 0.000 description 10
102000004127 Cytokines Human genes 0.000 description 9
108090000695 Cytokines Proteins 0.000 description 9
102000018697 Membrane Proteins Human genes 0.000 description 9
108010052285 Membrane Proteins Proteins 0.000 description 9
239000000872 buffer Substances 0.000 description 9
210000004899 c-terminal region Anatomy 0.000 description 9
239000007788 liquid Substances 0.000 description 9
210000004379 membrane Anatomy 0.000 description 9
239000012528 membrane Substances 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
229920000936 Agarose Polymers 0.000 description 8
108010076504 Protein Sorting Signals Proteins 0.000 description 8
240000004808 Saccharomyces cerevisiae Species 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
230000010065 bacterial adhesion Effects 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
239000003085 diluting agent Substances 0.000 description 8
239000000499 gel Substances 0.000 description 8
230000028993 immune response Effects 0.000 description 8
230000036039 immunity Effects 0.000 description 8
230000002163 immunogen Effects 0.000 description 8
238000011081 inoculation Methods 0.000 description 8
230000035772 mutation Effects 0.000 description 8
239000002245 particle Substances 0.000 description 8
230000001681 protective effect Effects 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
235000000346 sugar Nutrition 0.000 description 8
238000012546 transfer Methods 0.000 description 8
238000005406 washing Methods 0.000 description 8
241000588724 Escherichia coli Species 0.000 description 7
241000282412 Homo Species 0.000 description 7
108010008212 Integrin alpha4beta1 Proteins 0.000 description 7
241000700605 Viruses Species 0.000 description 7
238000001042 affinity chromatography Methods 0.000 description 7
150000001720 carbohydrates Chemical class 0.000 description 7
210000002421 cell wall Anatomy 0.000 description 7
230000000295 complement effect Effects 0.000 description 7
235000018977 lysine Nutrition 0.000 description 7
239000007787 solid Substances 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
238000013518 transcription Methods 0.000 description 7
230000035897 transcription Effects 0.000 description 7
238000002255 vaccination Methods 0.000 description 7
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
241000283707 Capra Species 0.000 description 6
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
102100037114 Elongin-C Human genes 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
101001011859 Homo sapiens Elongin-A Proteins 0.000 description 6
101001011846 Homo sapiens Elongin-B Proteins 0.000 description 6
101000881731 Homo sapiens Elongin-C Proteins 0.000 description 6
101000836005 Homo sapiens S-phase kinase-associated protein 1 Proteins 0.000 description 6
241000124008 Mammalia Species 0.000 description 6
241000700159 Rattus Species 0.000 description 6
229920002684 Sepharose Polymers 0.000 description 6
238000010367 cloning Methods 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
238000010276 construction Methods 0.000 description 6
230000007423 decrease Effects 0.000 description 6
238000003018 immunoassay Methods 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000007912 intraperitoneal administration Methods 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 6
238000002372 labelling Methods 0.000 description 6
239000011159 matrix material Substances 0.000 description 6
239000012071 phase Substances 0.000 description 6
229950004354 phosphorylcholine Drugs 0.000 description 6
PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical group [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 6
230000002685 pulmonary effect Effects 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
150000003839 salts Chemical group 0.000 description 6
239000002356 single layer Substances 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
239000004094 surface-active agent Substances 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
238000013519 translation Methods 0.000 description 6
235000014469 Bacillus subtilis Nutrition 0.000 description 5
101150069831 CBP gene Proteins 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
108060003951 Immunoglobulin Proteins 0.000 description 5
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
241001494479 Pecora Species 0.000 description 5
206010040047 Sepsis Diseases 0.000 description 5
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 5
230000001464 adherent effect Effects 0.000 description 5
239000000556 agonist Substances 0.000 description 5
230000000181 anti-adherent effect Effects 0.000 description 5
238000013459 approach Methods 0.000 description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
230000008859 change Effects 0.000 description 5
239000013611 chromosomal DNA Substances 0.000 description 5
210000000349 chromosome Anatomy 0.000 description 5
230000002860 competitive effect Effects 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
238000001962 electrophoresis Methods 0.000 description 5
210000002919 epithelial cell Anatomy 0.000 description 5
239000013604 expression vector Substances 0.000 description 5
230000002068 genetic effect Effects 0.000 description 5
102000018358 immunoglobulin Human genes 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
238000011160 research Methods 0.000 description 5
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 5
239000008215 water for injection Substances 0.000 description 5
102000014914 Carrier Proteins Human genes 0.000 description 4
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 4
102000002356 Nectin Human genes 0.000 description 4
108060005251 Nectin Proteins 0.000 description 4
108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
238000012300 Sequence Analysis Methods 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 4
239000003911 antiadherent Substances 0.000 description 4
230000003115 biocidal effect Effects 0.000 description 4
235000014633 carbohydrates Nutrition 0.000 description 4
238000012512 characterization method Methods 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
239000002270 dispersing agent Substances 0.000 description 4
239000000975 dye Substances 0.000 description 4
230000003511 endothelial effect Effects 0.000 description 4
230000004927 fusion Effects 0.000 description 4
108020001507 fusion proteins Proteins 0.000 description 4
102000037865 fusion proteins Human genes 0.000 description 4
230000002414 glycolytic effect Effects 0.000 description 4
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
210000004408 hybridoma Anatomy 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
230000000984 immunochemical effect Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
230000003993 interaction Effects 0.000 description 4
238000002955 isolation Methods 0.000 description 4
239000002502 liposome Substances 0.000 description 4
239000008263 liquid aerosol Substances 0.000 description 4
239000006166 lysate Substances 0.000 description 4
229920002521 macromolecule Polymers 0.000 description 4
210000001989 nasopharynx Anatomy 0.000 description 4
239000006199 nebulizer Substances 0.000 description 4
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
101150080370 pspA gene Proteins 0.000 description 4
238000011084 recovery Methods 0.000 description 4
230000009467 reduction Effects 0.000 description 4
238000012552 review Methods 0.000 description 4
230000009870 specific binding Effects 0.000 description 4
230000001629 suppression Effects 0.000 description 4
230000001131 transforming effect Effects 0.000 description 4
230000032258 transport Effects 0.000 description 4
239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
239000004215 Carbon black (E152) Substances 0.000 description 3
235000019743 Choline chloride Nutrition 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
102000008186 Collagen Human genes 0.000 description 3
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
241000282326 Felis catus Species 0.000 description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
108090001090 Lectins Proteins 0.000 description 3
102000004856 Lectins Human genes 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
101001021261 Pedobacter heparinus (strain ATCC 13125 / DSM 2366 / CIP 104194 / JCM 7457 / NBRC 12017 / NCIMB 9290 / NRRL B-14731 / HIM 762-3) Heparin and heparin-sulfate lyase Proteins 0.000 description 3
102000003992 Peroxidases Human genes 0.000 description 3
208000035109 Pneumococcal Infections Diseases 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
241000194019 Streptococcus mutans Species 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
239000013543 active substance Substances 0.000 description 3
230000001070 adhesive effect Effects 0.000 description 3
238000007818 agglutination assay Methods 0.000 description 3
238000010171 animal model Methods 0.000 description 3
238000000889 atomisation Methods 0.000 description 3
210000002469 basement membrane Anatomy 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
239000007975 buffered saline Substances 0.000 description 3
239000004067 bulking agent Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 3
229960003178 choline chloride Drugs 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
238000013270 controlled release Methods 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
239000008121 dextrose Substances 0.000 description 3
238000010586 diagram Methods 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
210000000981 epithelium Anatomy 0.000 description 3
239000008103 glucose Substances 0.000 description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
235000004554 glutamine Nutrition 0.000 description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
229930195733 hydrocarbon Natural products 0.000 description 3
150000002430 hydrocarbons Chemical class 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
238000009169 immunotherapy Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
239000002523 lectin Substances 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
244000144972 livestock Species 0.000 description 3
230000004807 localization Effects 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
244000005700 microbiome Species 0.000 description 3
230000009871 nonspecific binding Effects 0.000 description 3
229940023146 nucleic acid vaccine Drugs 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
108040007629 peroxidase activity proteins Proteins 0.000 description 3
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
238000011533 pre-incubation Methods 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
239000003380 propellant Substances 0.000 description 3
230000010076 replication Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
238000002741 site-directed mutagenesis Methods 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
230000009466 transformation Effects 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
235000002374 tyrosine Nutrition 0.000 description 3
210000003606 umbilical vein Anatomy 0.000 description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
NJNWCIAPVGRBHO-UHFFFAOYSA-N 2-hydroxyethyl-dimethyl-[(oxo-$l^{5}-phosphanylidyne)methyl]azanium Chemical group OCC[N+](C)(C)C#P=O NJNWCIAPVGRBHO-UHFFFAOYSA-N 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
241000486679 Antitype Species 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
241000271566 Aves Species 0.000 description 2
241000193830 Bacillus <bacterium> Species 0.000 description 2
208000031729 Bacteremia Diseases 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
241000186216 Corynebacterium Species 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
241000206602 Eukaryota Species 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
108010002231 IgA-specific serine endopeptidase Proteins 0.000 description 2
235000019766 L-Lysine Nutrition 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
235000019687 Lamb Nutrition 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
201000009906 Meningitis Diseases 0.000 description 2
102000016943 Muramidase Human genes 0.000 description 2
108010014251 Muramidase Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
108010021466 Mutant Proteins Proteins 0.000 description 2
102000008300 Mutant Proteins Human genes 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
239000002033 PVDF binder Substances 0.000 description 2
102000057297 Pepsin A Human genes 0.000 description 2
108090000284 Pepsin A Proteins 0.000 description 2
102000010562 Peptide Elongation Factor G Human genes 0.000 description 2
108010077742 Peptide Elongation Factor G Proteins 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
101710099976 Photosystem I P700 chlorophyll a apoprotein A1 Proteins 0.000 description 2
108010003541 Platelet Activating Factor Proteins 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
101710194807 Protective antigen Proteins 0.000 description 2
241000589516 Pseudomonas Species 0.000 description 2
241000700584 Simplexvirus Species 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
206010061372 Streptococcal infection Diseases 0.000 description 2
241000187747 Streptomyces Species 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
241000283068 Tapiridae Species 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
108700009124 Transcription Initiation Site Proteins 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
108700005077 Viral Genes Proteins 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
238000012387 aerosolization Methods 0.000 description 2
239000008272 agar Substances 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
108010027597 alpha-chymotrypsin Proteins 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
230000001078 anti-cholinergic effect Effects 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
229960001212 bacterial vaccine Drugs 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
229910002091 carbon monoxide Inorganic materials 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
238000004140 cleaning Methods 0.000 description 2
239000004020 conductor Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
230000008021 deposition Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000009510 drug design Methods 0.000 description 2
229940124274 edetate disodium Drugs 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
210000002744 extracellular matrix Anatomy 0.000 description 2
238000000855 fermentation Methods 0.000 description 2
230000004151 fermentation Effects 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000036541 health Effects 0.000 description 2
108060003552 hemocyanin Proteins 0.000 description 2
239000003547 immunosorbent Substances 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000010354 integration Effects 0.000 description 2
108010044426 integrins Proteins 0.000 description 2
102000006495 integrins Human genes 0.000 description 2
230000006799 invasive growth in response to glucose limitation Effects 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
231100000518 lethal Toxicity 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
108010052968 leupeptin Proteins 0.000 description 2
230000007774 longterm Effects 0.000 description 2
235000010335 lysozyme Nutrition 0.000 description 2
239000003550 marker Substances 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
239000003094 microcapsule Substances 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
229940051921 muramidase Drugs 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
229940111202 pepsin Drugs 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
229920002981 polyvinylidene fluoride Polymers 0.000 description 2
239000013641 positive control Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
230000006798 recombination Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
230000004044 response Effects 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000008347 soybean phospholipid Substances 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
229940031626 subunit vaccine Drugs 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
235000008521 threonine Nutrition 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
210000003556 vascular endothelial cell Anatomy 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
SBKVPJHMSUXZTA-MEJXFZFPSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 SBKVPJHMSUXZTA-MEJXFZFPSA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
XGIKILRODBEJIL-UHFFFAOYSA-N 1-(ethylamino)ethanol Chemical compound CCNC(C)O XGIKILRODBEJIL-UHFFFAOYSA-N 0.000 description 1
BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
OHMHBGPWCHTMQE-UHFFFAOYSA-N 2,2-dichloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)C(Cl)Cl OHMHBGPWCHTMQE-UHFFFAOYSA-N 0.000 description 1
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
102100028220 ABI gene family member 3 Human genes 0.000 description 1
101150056293 AJUBA gene Proteins 0.000 description 1
102000013563 Acid Phosphatase Human genes 0.000 description 1
108010051457 Acid Phosphatase Proteins 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
108010032595 Antibody Binding Sites Proteins 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
208000034309 Bacterial disease carrier Diseases 0.000 description 1
101100348617 Candida albicans (strain SC5314 / ATCC MYA-2876) NIK1 gene Proteins 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
102100035882 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
241000193163 Clostridioides difficile Species 0.000 description 1
241000193401 Clostridium acetobutylicum Species 0.000 description 1
241000193464 Clostridium sp. Species 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
241000186031 Corynebacteriaceae Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
102400000686 Endothelin-1 Human genes 0.000 description 1
101800004490 Endothelin-1 Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
101710145505 Fiber protein Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
229910052688 Gadolinium Inorganic materials 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
102000053187 Glucuronidase Human genes 0.000 description 1
108010060309 Glucuronidase Proteins 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
238000006852 Griffith reaction Methods 0.000 description 1
101000724234 Homo sapiens ABI gene family member 3 Proteins 0.000 description 1
101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
102000004867 Hydro-Lyases Human genes 0.000 description 1
108090001042 Hydro-Lyases Proteins 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
102100032818 Integrin alpha-4 Human genes 0.000 description 1
102100032817 Integrin alpha-5 Human genes 0.000 description 1
108010041014 Integrin alpha5 Proteins 0.000 description 1
108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
102100025304 Integrin beta-1 Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
229910001374 Invar Inorganic materials 0.000 description 1
150000008575 L-amino acids Chemical group 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
108010000817 Leuprolide Proteins 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108010038049 Mating Factor Proteins 0.000 description 1
101710085938 Matrix protein Proteins 0.000 description 1
101710127721 Membrane protein Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001024304 Mino Species 0.000 description 1
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
101710171321 Neuraminyllactose-binding hemagglutinin Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
108010061952 Orosomucoid Proteins 0.000 description 1
102000012404 Orosomucoid Human genes 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
101150012394 PHO5 gene Proteins 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
206010034133 Pathogen resistance Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
108010013639 Peptidoglycan Proteins 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
241000287462 Phalacrocorax carbo Species 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
235000011613 Pinus brutia Nutrition 0.000 description 1
241000018646 Pinus brutia Species 0.000 description 1
102000013566 Plasminogen Human genes 0.000 description 1
108010051456 Plasminogen Proteins 0.000 description 1
108700023400 Platelet-activating factor receptors Proteins 0.000 description 1
241001582367 Polia Species 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
241001505332 Polyomavirus sp. Species 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
230000004570 RNA-binding Effects 0.000 description 1
101000898061 Rattus norvegicus Calumenin Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
241000208422 Rhododendron Species 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
101100007329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS1 gene Proteins 0.000 description 1
101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
108091003202 SecA Proteins Proteins 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
244000061458 Solanum melongena Species 0.000 description 1
235000002597 Solanum melongena Nutrition 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
241000282887 Suidae Species 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
241000221484 Tilletiaceae Species 0.000 description 1
241001504592 Trachurus trachurus Species 0.000 description 1
GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
241001504505 Troglodytes troglodytes Species 0.000 description 1
108010030743 Tropomyosin Proteins 0.000 description 1
102000005937 Tropomyosin Human genes 0.000 description 1
108090001027 Troponin Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
238000003916 acid precipitation Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
102000019997 adhesion receptor Human genes 0.000 description 1
108010013985 adhesion receptor Proteins 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229940037003 alum Drugs 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
238000003277 amino acid sequence analysis Methods 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
238000004082 amperometric method Methods 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000002519 antifouling agent Substances 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
238000003491 array Methods 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
JPIYZTWMUGTEHX-UHFFFAOYSA-N auramine O free base Chemical compound C1=CC(N(C)C)=CC=C1C(=N)C1=CC=C(N(C)C)C=C1 JPIYZTWMUGTEHX-UHFFFAOYSA-N 0.000 description 1
230000029586 bacterial cell surface binding Effects 0.000 description 1
230000037358 bacterial metabolism Effects 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000008955 bacterial trafficking Effects 0.000 description 1
230000010310 bacterial transformation Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
229960004261 cefotaxime Drugs 0.000 description 1
AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
238000004581 coalescence Methods 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
239000000599 controlled substance Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
BABWHSBPEIVBBZ-UHFFFAOYSA-N diazete Chemical compound C1=CN=N1 BABWHSBPEIVBBZ-UHFFFAOYSA-N 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
238000002050 diffraction method Methods 0.000 description 1
125000005442 diisocyanate group Chemical group 0.000 description 1
239000000539 dimer Substances 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
229940126534 drug product Drugs 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000005868 electrolysis reaction Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
235000020774 essential nutrients Nutrition 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
235000013305 food Nutrition 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
238000010230 functional analysis Methods 0.000 description 1
UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
108090001082 glucan-binding proteins Proteins 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
239000003292 glue Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
208000027136 gram-positive bacterial infections Diseases 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
210000001822 immobilized cell Anatomy 0.000 description 1
230000005934 immune activation Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
238000000760 immunoelectrophoresis Methods 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000006054 immunological memory Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000003017 in situ immunoassay Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
238000002743 insertional mutagenesis Methods 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
108010083708 leucyl-aspartyl-valine Proteins 0.000 description 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
229960004338 leuprorelin Drugs 0.000 description 1
230000031700 light absorption Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
101150082581 lytA gene Proteins 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011572 manganese Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000013507 mapping Methods 0.000 description 1
229940127554 medical product Drugs 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000001114 myogenic effect Effects 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
238000001683 neutron diffraction Methods 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
239000011022 opal Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
101150078860 pho gene Proteins 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
238000005375 photometry Methods 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
238000009832 plasma treatment Methods 0.000 description 1
238000013492 plasmid preparation Methods 0.000 description 1
102000030769 platelet activating factor receptor Human genes 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
244000144977 poultry Species 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
229940021993 prophylactic vaccine Drugs 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000013197 protein A assay Methods 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000000734 protein sequencing Methods 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
230000005855 radiation Effects 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
239000012857 radioactive material Substances 0.000 description 1
238000011552 rat model Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000012465 retentate Substances 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
102220057255 rs730881172 Human genes 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000003579 shift reagent Substances 0.000 description 1
239000013605 shuttle vector Substances 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000022379 skeletal muscle tissue development Effects 0.000 description 1
229940083538 smallpox vaccine Drugs 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
229940031008 streptococcus mutans Drugs 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229910052713 technetium Inorganic materials 0.000 description 1
GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
238000010998 test method Methods 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
238000003325 tomography Methods 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
239000006150 trypticase soy agar Substances 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000007279 water homeostasis Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000012130 whole-cell lysate Substances 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

JP09539170A 1996-05-01 1997-05-01 抗―肺炎球菌ワクチン用のコリン結合タンパク質 Pending JP2000511411A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US1663296P	1996-05-01	1996-05-01
US64225096A	1996-05-01	1996-05-01
US60/016,632		1996-05-01
US08/642,250		1996-05-01
PCT/US1997/007198 WO1997041151A2 (en)	1996-05-01	1997-05-01	Choline binding proteins for anti-pneumococcal vaccines

Publications (2)

Publication Number	Publication Date
JP2000511411A true JP2000511411A (ja)	2000-09-05
JP2000511411A5 JP2000511411A5 (2)	2005-01-13

Family

ID=26688869

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP09539170A Pending JP2000511411A (ja)	1996-05-01	1997-05-01	抗―肺炎球菌ワクチン用のコリン結合タンパク質

Country Status (8)

Country	Link
EP (1)	EP0912608B1 (2)
JP (1)	JP2000511411A (2)
AT (1)	ATE323721T1 (2)
AU (1)	AU732520B2 (2)
CA (1)	CA2253252A1 (2)
DE (1)	DE69735715T2 (2)
ES (1)	ES2262177T3 (2)
WO (1)	WO1997041151A2 (2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5197846B2 (ja) *	2009-04-30	2013-05-15	紀陽田仲	腎疾患重篤度を判定する方法又は装置若しくはその作動方法
JP2023502994A (ja) *	2019-11-18	2023-01-26	バックスサイト・インコーポレイテッド	動物産物を含まないレンサ球菌の培養

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7078042B2 (en)	1995-09-15	2006-07-18	Uab Research Foundation	Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
US6245335B1 (en)	1996-05-01	2001-06-12	The Rockefeller University	Choline binding proteins for anti-pneumococcal vaccines
WO1998021337A2 (en) *	1996-11-12	1998-05-22	Regents Of The University Of Minnesota	C3 BINDING PROTEIN OF $i(STREPTOCOCCUS PNEUMONIAE)
DE19708537A1 (de) *	1997-03-03	1998-09-10	Biotechnolog Forschung Gmbh	Neues Oberflächenprotein (SpsA-Protein) von Streptococcus pneumoniae etc.
US6676943B1 (en)	1997-04-24	2004-01-13	Regents Of The University Of Minnesota	Human complement C3-degrading protein from Streptococcus pneumoniae
DE69942176D1 (de) *	1998-04-07	2010-05-06	Medimmune Llc	Choline-bindende proteine derivate aus pneumokoken als impfstoff
US6858706B2 (en)	1998-04-07	2005-02-22	St. Jude Children's Research Hospital	Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
TR200003498T2 (tr) *	1998-04-07	2001-10-22	St. Jude Children's Research Hospital	Amino asit sekansından oluşan bir polipetit, bunun aşıları ve kullanımları
AU2004200125B2 (en) *	1998-04-07	2006-07-27	Med Immune, Inc.	Derivatives of Pneumococcal Choline Binding Proteins for Vaccines
US20010016200A1 (en)	1998-04-23	2001-08-23	Briles David E.	Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
WO2000029434A2 (en) *	1998-11-19	2000-05-25	St. Jude Children's Research Hospital	PNEUMOCOCCAL CHOLINE BINDING PROTEINS, CbpG AND CbpD, DIAGNOSTIC AND THERAPEUTIC USES THEREOF
US6495139B2 (en)	1998-11-19	2002-12-17	St. Jude Children's Research Hospital	Identification and characterization of novel pneumococcal choline binding protein, CBPG, and diagnostic and therapeutic uses thereof
ES2322306T3 (es)	1998-12-21	2009-06-18	Medimmune, Inc.	Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas.
ES2275499T3 (es)	1999-03-19	2007-06-16	Glaxosmithkline Biologicals S.A.	Vacuna contra streptococcus pneumoniae.
GB9918319D0 (en)	1999-08-03	1999-10-06	Smithkline Beecham Biolog	Vaccine composition
GB0022742D0 (en)	2000-09-15	2000-11-01	Smithkline Beecham Biolog	Vaccine
EP1524991A1 (en)	2002-08-02	2005-04-27	GlaxoSmithKline Biologicals S.A.	Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
EP2395073B1 (en)	2002-11-01	2017-09-06	GlaxoSmithKline Biologicals S.A.	Drying process
DE602004028262D1 (de)	2003-10-02	2010-09-02	Glaxosmithkline Biolog Sa	B. pertussis antigene und ihre verwendung bei der vakzinierung
GB0505996D0 (en)	2005-03-23	2005-04-27	Glaxosmithkline Biolog Sa	Fermentation process
TWI457133B (zh)	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
GB0607088D0 (en)	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
PL1973564T3 (pl)	2005-12-22	2017-04-28	Glaxosmithkline Biologicals S.A.	Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
AU2007206114B2 (en)	2006-01-17	2013-01-24	Arne Forsgren	A novel surface exposed Haemophilus influenzae protein (protein E; pE)
SI2167121T1 (sl)	2007-06-26	2015-12-31	Glaxosmithkline Biologicals S.A.	Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
SI2271360T1 (sl)	2008-04-16	2015-12-31	Glaxosmithkline Biologicals S.A.	Cepivo
GB201003924D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Immunogenic composition
EP2544714A1 (en)	2010-03-10	2013-01-16	GlaxoSmithKline Biologicals S.A.	Vaccine composition
GB201015132D0 (en)	2010-09-10	2010-10-27	Univ Bristol	Vaccine composition
WO2012156391A1 (en)	2011-05-17	2012-11-22	Glaxosmithkline Biologicals S.A.	Vaccine against streptococcus pneumoniae
WO2014186796A1 (en)	2013-05-17	2014-11-20	The Board Of Regents Of The University Of Texas System	Immunization to protect against adverse cardiac events relating to pneumococcal infection
GB201518684D0 (en)	2015-10-21	2015-12-02	Glaxosmithkline Biolog Sa	Vaccine
GB201711635D0 (en)	2017-07-19	2017-08-30	Glaxosmithkline Biologicals Sa	Immunogenic composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU4400293A (en) *	1992-05-29	1993-12-30	Janet Yother	Methods for obtaining and purifying cell-free pneumococcal surface proteins from (s. pneumoniae) and use thereof
CA2116261A1 (en) *	1993-04-20	1994-10-21	David E. Briles	Epitopic regions of pneumococcal surface protein a
CZ394297A3 (cs) *	1995-06-07	1998-04-15	Biochem Vaccines Inc.	Streptokokové proteiny teplotního šoku ze skupiny HSP70

1997
- 1997-05-01 DE DE69735715T patent/DE69735715T2/de not_active Expired - Lifetime
- 1997-05-01 ES ES97922539T patent/ES2262177T3/es not_active Expired - Lifetime
- 1997-05-01 CA CA002253252A patent/CA2253252A1/en not_active Abandoned
- 1997-05-01 AU AU28182/97A patent/AU732520B2/en not_active Ceased
- 1997-05-01 JP JP09539170A patent/JP2000511411A/ja active Pending
- 1997-05-01 EP EP97922539A patent/EP0912608B1/en not_active Expired - Lifetime
- 1997-05-01 WO PCT/US1997/007198 patent/WO1997041151A2/en not_active Ceased
- 1997-05-01 AT AT97922539T patent/ATE323721T1/de not_active IP Right Cessation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5197846B2 (ja) *	2009-04-30	2013-05-15	紀陽田仲	腎疾患重篤度を判定する方法又は装置若しくはその作動方法
JP2023502994A (ja) *	2019-11-18	2023-01-26	バックスサイト・インコーポレイテッド	動物産物を含まないレンサ球菌の培養

Also Published As

Publication number	Publication date
AU2818297A (en)	1997-11-19
ATE323721T1 (de)	2006-05-15
ES2262177T3 (es)	2006-11-16
DE69735715T2 (de)	2007-03-29
AU732520B2 (en)	2001-04-26
DE69735715D1 (de)	2006-05-24
CA2253252A1 (en)	1997-11-06
EP0912608B1 (en)	2006-04-19
WO1997041151A2 (en)	1997-11-06
EP0912608A2 (en)	1999-05-06

Legal Events

Date	Code	Title	Description
2004-05-27	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040430
2004-05-27	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040430
2007-06-12	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070612
2007-10-04	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070912
2007-10-22	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071022
2008-01-10	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071212
2008-03-25	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080325

Publication	Publication Date	Title
JP2000511411A (ja)	2000-09-05	抗―肺炎球菌ワクチン用のコリン結合タンパク質
US7425327B2 (en)	2008-09-16	Choline binding proteins for anti-pneumococcal vaccines
WO1997041151A9 (en)	1998-03-12	Choline binding proteins for anti-pneumococcal vaccines
EP1320542B1 (en)	2007-04-25	Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
US20080009022A1 (en)	2008-01-10	Immunization of dairy cattle with chimeric gapC protein against streptococcus infection
US8529912B2 (en)	2013-09-10	Group B Streptococcus polypeptides, nucleic acids and therapeutic compositions and vaccines thereof
US6495139B2 (en)	2002-12-17	Identification and characterization of novel pneumococcal choline binding protein, CBPG, and diagnostic and therapeutic uses thereof
JPH09502604A (ja)	1997-03-18	Ｃａｍｐｙｌｏｂａｃｔｅｒｊｅｊｕｎｉ抗原、並びにそれらの製造及び利用
US6406883B1 (en)	2002-06-18	Lmb gene of Streptococcus agalactiae
WO2000029434A2 (en)	2000-05-25	PNEUMOCOCCAL CHOLINE BINDING PROTEINS, CbpG AND CbpD, DIAGNOSTIC AND THERAPEUTIC USES THEREOF
WO1999016882A1 (en)	1999-04-08	LMB GENE OF $i(STREPTOCOCCUS AGALACTIAE)
JP2002533084A (ja)	2002-10-08	Ａ群のＳｔｒｅｐｔｏｃｏｃｃｉの防御的な抗原（ＳＰＡ）
EP1332155B1 (en)	2006-10-25	Immunization of dairy cattle with gapc protein against streptococcus infection
JPH10215882A (ja)	1998-08-18	新規トリプトファニルｔＲＮＡシンセターゼ
JP2001504335A (ja)	2001-04-03	ストレプトコッカス・ユベリスのラクトフェリン結合タンパク質
US20030082781A1 (en)	2003-05-01	Immunization of dairy cattle with GapC protein against Streptococcus infection
JP2005514052A (ja)	2005-05-19	Ｂ群連鎖球菌の新規の細胞表面プロテアーゼの使用
JPH1198983A (ja)	1999-04-13	新規ａｒｇＳ
JP2000102385A (ja)	2000-04-11	ｄｅｆ１

JP2000511411A - 抗―肺炎球菌ワクチン用のコリン結合タンパク質 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (5)

Publications (2)

Family

ID=26688869

Family Applications (1)

Country Status (8)

Cited By (2)

Families Citing this family (33)

Family Cites Families (3)

Cited By (2)

Also Published As

Similar Documents

Legal Events